

Gemigliptin, metformin combo beats monotherapy in T2DM

September 20 2016



(HealthDay)—Gemigliptin combined with metformin is superior to

monotherapy with either drug for patients with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 13 in *Diabetes, Obesity and Metabolism*.

Soo Lim, M.D., Ph.D., from the Seoul National University College of Medicine in South Korea, and colleagues randomized 433 patients with T2DM with a glycosylated hemoglobin (HbA1c) level of 7.5 to 11.0 percent and fasting plasma glucose concentration

Citation: Gemigliptin, metformin combo beats monotherapy in T2DM (2016, September 20) retrieved 28 April 2024 from <https://medicalxpress.com/news/2016-09-gemigliptin-metformin-combo-monotherapy-t2dm.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--